I've been tracking inflammatory markers closely in my patients on GLP-1 receptor agonists, and I want to share a particularly striking case (with patient permission) alongside the broader data.
Patient: 58F, BMI 39.4, T2DM (A1C 8.1%), hypertension, on atorvastatin 40mg. Started semaglutide 2.4 mg. Inflammatory panel over 14 months:
| Marker | Baseline | 6 Months | 14 Months | Reference Range |
|---|---|---|---|---|
| hsCRP (mg/L) | 8.4 | 2.1 | 0.6 | <1.0 low risk; 1-3 moderate; >3 high |
| IL-6 (pg/mL) | 6.8 | 3.2 | 1.4 | <1.8 |
| TNF-α (pg/mL) | 12.4 | 7.1 | 4.8 | <8.1 |
| Fibrinogen (mg/dL) | 468 | 342 | 298 | 200-400 |
| Ferritin (ng/mL) | 312 | 188 | 142 | 12-150 |
The hsCRP reduction from 8.4 to 0.6 mg/L represents a 93% decline. This patient went from the highest cardiovascular risk category to the lowest based on hsCRP alone.
"In the SELECT trial, semaglutide reduced hsCRP by approximately 38% from baseline, with greater reductions observed in patients with higher baseline levels."[1]
The question I keep wrestling with: how much of the CV benefit we saw in SELECT is mediated by this anti-inflammatory effect?
[1] Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232.
This is a fantastic dataset. The concordance across multiple inflammatory markers (CRP, IL-6, TNF-α, fibrinogen, ferritin) argues strongly against a spurious single-marker finding. This is genuine systemic inflammation resolution.
To your question about mediation: the CANTOS trial provides an important framework. Canakinumab (anti-IL-1β monoclonal antibody) reduced hsCRP by ~35% and MACE by 15% (HR 0.85 for the 150mg dose) without affecting lipids at all.[1] This proved that inflammation is a causal pathway in atherosclerosis, not just a marker.
In SELECT's mediation analyses, hsCRP reduction explained approximately 28% of the MACE benefit — more than weight loss, more than any single metabolic parameter. The remaining benefit likely comes from:
- Direct anti-atherosclerotic effects (reduced monocyte adhesion, improved endothelial function)
- Reduced visceral adiposity (the primary source of IL-6 and TNF-α)
- Improved hepatic steatosis (the liver is a major CRP producer)
[1] Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease (CANTOS). N Engl J Med. 2017;377(12):1119-1131.
My hsCRP story isn't as dramatic but still notable. Started at 5.2 mg/L with a BMI of 33 and prediabetes. After 9 months on semaglutide 1.7 mg (insurance won't cover 2.4):
- hsCRP: 5.2 → 1.8 mg/L (65% reduction)
- A1C: 6.3% → 5.4%
- Weight: 218 → 186 lbs
What I find interesting is that my hsCRP plateaued at 1.8 for the past 3 months despite continued slow weight loss. Is there a floor effect, or would going to 2.4 mg push it lower?
Janoshik Analytical — Independent Testing
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesGL Biochem (Shanghai) Ltd. — Direct Manufacturer
Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemThere may be a physiological floor for hsCRP reduction depending on the underlying inflammatory milieu. An hsCRP of 1.8 mg/L puts you in the "moderate risk" category and represents a very meaningful improvement from 5.2.
Several factors can maintain residual inflammation even with weight loss and GLP-1 therapy:
- Remaining visceral adipose tissue (even at a normal BMI, visceral fat distribution matters)
- Gut microbiome composition (persistent dysbiosis can drive low-grade endotoxemia)
- Sleep quality (sleep disruption increases IL-6 and CRP)
- Chronic stress (cortisol-inflammation axis)
- Periodontal disease (often overlooked contributor to systemic CRP elevation)
Before escalating the semaglutide dose, I'd investigate these modifiable factors. Dental health is one I've seen make a surprising difference — treating periodontitis can drop hsCRP by 0.5-1.0 mg/L.
To add population-level context on CRP reduction across the GLP-1 trials:
| Trial | Drug / Dose | Baseline hsCRP (median) | % Reduction vs. Placebo |
|---|---|---|---|
| SELECT | Sema 2.4 mg | 3.5 mg/L | ~38% |
| SUSTAIN-6 | Sema 0.5 / 1.0 mg | ~2.8 mg/L | ~25% |
| STEP 1 | Sema 2.4 mg | ~3.0 mg/L | ~34% |
| SURPASS-4 | Tirz 5/10/15 mg | ~3.2 mg/L | ~32-40% |
Higher baseline CRP predicts greater absolute (but not always percentage) reductions. The patient in the OP's case with a baseline of 8.4 mg/L was starting from a markedly inflammatory state, which likely explains the dramatic absolute decline.
For reference, each doubling of hsCRP is associated with an approximately 1.4-fold increase in MACE risk. Going from 8.4 to 0.6 represents a massive shift in predicted risk.